Abstract
Zygomycosis is increasingly reported as a cause of life-threatening fungal infections. A higher proportion of cases reported over the last decades have been in cancer patients, with or without hematopoietic stem cell transplantation (HSCT). The new anti-fungal agent voriconazole is a recently identified risk factor for developing zygomycosis. We reviewed the clinical characteristics and outcomes of a large cohort of cancer patients who developed zygomycosis after exposure to voriconazole. Health care professionals at 13 large cancer centers provided clinical information on cancer patients with zygomycosis and prior exposure to voriconazole. Criteria for inclusion were 5 days or more of voriconazole use and diagnostic confirmation with tissue or histology. Fifty-eight cases were identified among patients with hematologic malignancies, 62% including patients who underwent a HSCT procedure. Fifty-six patients received voriconazole for primary or secondary prophylaxis against fungal infection. In addition to prior exposure to voriconazole, patients also had several of the previously established risk factors for zygomycosis. Amphotericin B was the most commonly prescribed anti-fungal therapy. Overall mortality was 73%. We conclude that zygomycosis after exposure to voriconazole is a recently described entity that is frequently fatal, despite treatment with currently available anti-fungal agents and surgery.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634–653.
Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP . Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005; 41: 60–66.
Marty FM, Cosimi LA, Baden LR . Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950–952.
Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA . Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743–746.
Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, Bartelt LA, Kilborn SB, Hoth PL et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39: 584–587.
Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C et al. Zygomycosis in a tertiary care cancer center in the era of Aspergillus-active antifungal therapy: a case control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350–1360.
Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR . In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581–1582.
Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM et al. The Research on Adverse Drug Events and Report (RADAR) project. JAMA 2005; 293: 2131–2140.
Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.
Yarnold PR, Soltysik RC . Optimal Data Analysis: Guidebook with Software for Windows. APA Books: Washington, DC, 2005.
Spellberg B, Edwards Jr J, Ibrahim A . Novel perspectives on Mucormycosis: pathophysiology, presentation and management. Clin Microbiol Rev 2005; 18: 556–569.
Spellberg B, Fu Y, Edwards Jr JE, Ibrahim AS . Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005; 49: 830–832.
Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50: 126–133.
van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP . Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61–e65 (E-pub 2006 Feb 21; erratum in Clin infect Dis 2006; 43: 1376).
Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009–2015.
Rickerts V, Bohme A, Just-Nubling G . Risk factor for invasive zygomycosis in patients with hematologic malignancies. Mycoses 2002; 45 (Suppl 1): 27–30.
Marr KA, Seidel K, White TC, Bowden RA . Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309–316.
Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35: 509–513.
Trifilio S, Singhal S, Williams S, Winter J, Tallman M, Gordon L et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Blood (ASH Annual Meeting Abstracts) 2006, Abstract number 2849.
Siwek GT, Pfaller MA, Polgreen PM, Cobb S, Hoth P, Magalheas-Silverman M et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis 2006; 55: 209–212.
Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391–1402.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Trifilio, S., Bennett, C., Yarnold, P. et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 39, 425–429 (2007). https://doi.org/10.1038/sj.bmt.1705614
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705614
Keywords
This article is cited by
-
Fatal disseminated mucormycosis due to Cunninghamella bertholletiae infection after ABO-incompatible living donor liver transplantation: a case report
Surgical Case Reports (2022)
-
Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19
Environmental Science and Pollution Research (2022)
-
Mucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy
Annals of Intensive Care (2020)